Pharmaceuticals giant Roche blasted for refusing to make breast cancer drug Kadcyla affordable

 

Health Correspondent

The drugs giant Roche has been accused of blocking hundreds of terminal cancer patients from receiving a life-extending drug, by refusing to cut costs to make it affordable for the NHS.

Roche’s drug Kadcyla can extend life by six months longer than the next best treatment, but will not be available on the NHS because of its £90,000-per-patient price-tag, the National Institute for Health and Care Excellence (NICE) confirmed today, in final draft guidance.

The drug, which is recommended for women with HER2-positive breast cancer whose treatment with other drugs and chemotherapy has failed, is available in England through the £200m Cancer Drugs Fund, but is only released on case-by-case basis.

Had the drug been made available on the NHS, it would have reached around 1,500 women.

Sir Andrew Dillon, chief executive of NICE, said he was “really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation.” However, the Swiss pharmaceutical firm, which recorded profits of £7.4bn last year, hit back saying that it had offered a “significant discount”.

Dr Jayson Dallas, general manager of Roche Products Ltd accused NICE of an “incredible injustice” which was “tantamount to turning the clock back in cancer research and development.”

Breast cancer charities expressed disappointment at NICE’s decision, but also criticised Roche for the high price-tag.

Sally Greenbrook, senior policy officer at Breakthrough Breast Cancer said that Kadcyla was “incredibly expensive”.

“NICE have gone over and above their usual processes to try to approve it but despite this, and the discount offered by the manufacturer, the revised price for Kadcyla is still too high to be considered cost effective,” she said.

“We believe all cancer patients should be able to access the best possible treatment but for this to happen within the confines of the NHS budget, prices set by the pharmaceutical industry for impressive, life-extending drugs such as Kadcyla must come down. It’s impossible to put a price on life’s precious moments. But it’s not impossible to put a fair price on drugs.”

Dr Emma Pennery, clinical director at Breast Cancer Care, said it was “worrying” that every drug appraised by NICE for terminal breast cancer patients in the past three years had been rejected. She called on NICE, the Department of Health and the pharmaceutical industry to work together on “a new way forward”.

The Cancer Drugs Fund, which exists to pay for cancer drugs which the NHS does not ordinarily provide for cost reasons, is set to terminate in 2016.

A spokesperson for Roche said that a discount of 60 per cent would have been required to meet NICE’s requirements for cost-efficiency – a rate which was described as “unrealistic”. The company could not disclose the actual rate of discount it had offered NICE.

According to Rohce, Kadcyla took 15 years to develop. It is already routinely available in several European countries.

Dr Pennery said that, as well as extending life, Kadcyla also had advantages over other drugs in terms of reducing side-effects and improving quality of life for terminally ill patients. 

“Patients having Kadcyla will have incurable disease. Knowing, that time becomes very precious,” she said. “Those extra six months might allow them to spend more time with loved ones, with families.”

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Area Sales Manager - Midlands

    £20000 - £25000 per annum: Recruitment Genius: This is an exciting opportunity...

    Recruitment Genius: PHP Developer - 3-4 Month Fixed Contract - £30-£35k pro rata

    £30000 - £35000 per annum: Recruitment Genius: This is a 3-4 month pro rata fi...

    Recruitment Genius: Telesales Executive - OTE £26,000+

    £16000 - £26000 per annum: Recruitment Genius: A Telesales Executive is requir...

    Recruitment Genius: Area Sales Manager

    £25000 per annum: Recruitment Genius: This is an exciting opportunity to join ...

    Day In a Page

    Seifeddine Rezgui: What motivated a shy student to kill 38 holidaymakers in Tunisia?

    Making of a killer

    What motivated a shy student to kill 38 holidaymakers in Tunisia?
    UK Heatwave: Temperatures on the tube are going to exceed the legal limit for transporting cattle

    Just when you thought your commute couldn't get any worse...

    Heatwave will see temperatures on the Tube exceed legal limit for transporting cattle
    Exclusive - The Real Stories of Migrant Britain: Swapping Bucharest for London

    The Real Stories of Migrant Britain

    Meet the man who swapped Romania for the UK in a bid to provide for his family, only to discover that the home he left behind wasn't quite what it seemed
    Cheaper energy on the way, but it's not all sunshine and rainbows

    Cheaper energy on the way, but it's not all sunshine and rainbows

    Solar power will help bring down electricity prices over the next five years, according to a new report. But it’s cheap imports of ‘dirty power’ that will lower them the most
    Katy Perry prevented from buying California convent for $14.5m after nuns sell to local businesswoman instead

    No grace of God for Katy Perry as sisters act to stop her buying convent

    Archdiocese sues nuns who turned down star’s $14.5m because they don’t approve of her
    Ajmer: The ancient Indian metropolis chosen to be a 'smart city' where residents would just be happy to have power and running water

    Residents just want water and power in a city chosen to be a ‘smart’ metropolis

    The Indian Government has launched an ambitious plan to transform 100 of its crumbling cities
    Michael Fassbender in 'Macbeth': The Scottish play on film, from Welles to Cheggers

    Something wicked?

    Films of Macbeth don’t always end well - just ask Orson Welles... and Keith Chegwin
    10 best sun creams for body

    10 best sun creams for body

    Make sure you’re protected from head to toe in the heatwave
    Wimbledon 2015: Nick Bollettieri - Milos Raonic has ability to get to the top but he must learn to handle pressure in big games

    Nick Bollettieri's Wimbledon files

    Milos Raonic has ability to get to the top but he must learn to handle pressure in big games
    Women's World Cup 2015: How England's semi-final success could do wonders for both sexes

    There is more than a shiny trophy to be won by England’s World Cup women

    The success of the decidedly non-famous females wearing the Three Lions could do wonders for a ‘man’s game’ riddled with cynicism and greed
    How to stop an asteroid hitting Earth: Would people co-operate to face down a global peril?

    How to stop an asteroid hitting Earth

    Would people cooperate to face a global peril?
    Just one day to find €1.6bn: Greece edges nearer euro exit

    One day to find €1.6bn

    Greece is edging inexorably towards an exit from the euro
    New 'Iron Man' augmented reality technology could help surgeons and firefighters, say scientists

    'Iron Man' augmented reality technology could become reality

    Holographic projections would provide extra information on objects in a person's visual field in real time
    Sugary drinks 'are killing 184,000 adults around the world every year'

    Sugary drinks are killing 184,000 adults around the world every year

    The drinks that should be eliminated from people's diets
    Pride of Place: Historians map out untold LGBT histories of locations throughout UK

    Historians map out untold LGBT histories

    Public are being asked to help improve the map